Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man

Xenobiotica

Volumn 32, Issue 9, 2002, Pages 823-831

  Katagi, M ^a   Tatsuno, M ^a   Tsutsumi, H ^a   Miki, A ^a   Kamata, T ^a   Nishioka, H ^a   Nakajima, K ^a   Nishikawa, M ^a   Tsuchihashi, H ^a  

^a OSAKA PREFECTURE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE; NORSELEGILINE; SELEGILINE; SELEGILINE N OXIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXCRETION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; SOLID PHASE EXTRACTION;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AMPHETAMINE; AMPHETAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN-ION CONCENTRATION; METHAMPHETAMINE; MODELS, CHEMICAL; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TIME FACTORS;

EID: 0036745811     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250210144857     Document Type: Article

References (19)

1. Bach, M. V., Coutts, R. T. and Baker, G. B., 2000, Metabolism of N,N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line. Xenobiotica, 30, 297-306.
2. Beckett, A. H. and Rowland, M., 1965, Urinary excretion kinetics of methyl-amphetamine in man. Journal of Pharmacy and Pharmacology, 17, 109S-114S.
3. Crossley, F. S. and Moore, M. L., 1944, Studies on the Leuckart reaction. Journal of Organic Chemistry, 9, 529-536.
4. Grace, J. M., Kinter, M. T. and MacDonald, T. L., 1994, Typical metabolism of deprenyl and its enantiomer, (S)-(+)-N, α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chemical Research in Toxicology, 7, 286-290.
5. Heinonen, E. H. and Lammintausta, R., 1991, A review of the pharmacology of selegiline. Acta Neurologica Scandinavica, 84(suppl.), 44-59.
6. Heinonen, E. H., Anttila, M. I. and Lammintausta, R. A., 1994, Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clinical Pharmacology and Therapeutics, 56, 742-749.
7. Hidestrand, M., Oscarson, M., Salonen, J. S., Nyman, L., Pelkonen, O., Turpeinen, M. and IngelmanSundberg, M., 2001, CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metabolism and Disposition, 29, 1480-1484.
8. Jenner, P., 1971, The role of nitrogen oxidation in the excretion of drugs and foreign compounds. Xenobiotica, 1, 399-418.
9. Katagi, M., Tatsuno, M., Miki, A., Nishikawa, M., Nakajima, K. and Tsuchihashi, H., 2001, Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. Journal of Chromatography B, 759, 125-133.
10. Knoll, J., 1978, The possible mechanisms of action of (-)deprenyl in Parkinson's disease. Journal of Neural Transmission, 43, 177-198.
11. Lemoine, A., Johann, M. and Cresteil, T., 1990, Evidence for the presence of distinct flavin-containing monooxygenases in human tissues. Archives of Biochemistry and Biophysics, 276, 336-342.
12. Lengyel, J., Magyar, K., Hollói, I., Bartók, T., Báthori, M., Kalász, H. and Fürst, S., 1997, Urinary excretion of deprenyl metabolites. Journal of Chromatography A, 762, 321-326.
13. Maurer, H. H. and Kraemer, T., 1992, Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Archives of Toxicology, 66, 675-678.
14. Poulsen, L. L. and Ziegler, D. M., 1979, The liver microsomal FAD-containing monooxygenase. Spectral characterization and kinetic studies. Journal of Biological Chemistry, 254, 6449-6455.
15. Shin, H. S., 1997, Metabolism of selegiline in humans. Identification; excretion, and stereochemistry of urine metabolites. Drug Metabolism and Disposition, 25, 657-662.
16. Szatmari, I. and Toth, K., 1992, Pharmacokinetics and metabolism of selegiline. Acta Pharmaceutica Hungarica, 62, 243-248.
17. Taavitsainen, P., Anttila, M., Nyman, L., Karnani, H., Salonen, J. S. and Pelkonen, O., 2000, Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacology and Toxicology, 86, 215-221.
18. Yamazaki, M., Islam, M. N., Takikita, S., Ogura, Y., Terada, M., Nakatome, M., Kuroki, H. and Honda, K., 1999, Immunohistochemical and enzymological studies of flavin (FAD)-containing monooxygenase in human liver. Japanese Journal of Forensic Toxicology, 17, 30-41.
19. Ziegler, D. M., 1988, Flavin-containing monooxygenase: catalytic mechanism and substrate specificities. Drug Metabolism Reviews, 19, 1-32.